The CDC5 antibody targets the CDC5 protein, a conserved eukaryotic protein involved in cell cycle regulation and pre-mRNA splicing. Initially identified in *Saccharomyces cerevisiae*, CDC5 (Cell Division Cycle 5) is a member of the *Saccharomyces cerevisiae* cdc gene family and shares homology with human proteins like DNA damage response regulators. Structurally, CDC5 contains a Myb-like DNA-binding domain and plays dual roles in promoting mitotic exit and facilitating spliceosome assembly during transcription.
In research, CDC5 antibodies are widely used to study cell cycle checkpoints, DNA repair mechanisms, and spliceosome dynamics. Studies in yeast models revealed that CDC5 depletion arrests cells in the G2/M phase, underscoring its role in mitosis. In humans, homologs like hCDC5 (or SPDL1) are implicated in cancer biology, where dysregulated expression correlates with genomic instability and tumor progression. CDC5 antibodies enable detection via techniques like Western blotting, immunofluorescence, and immunoprecipitation, aiding investigations into its interactions with cell cycle kinases (e.g., PLK1) and spliceosome components.
Recent work explores CDC5's potential as a therapeutic target, particularly in cancers with defective DNA repair pathways. Its conserved function across species makes it a valuable model for studying cell division and RNA processing. However, challenges remain in distinguishing its roles in mitosis versus splicing, highlighting the need for context-specific antibody applications.